Remote-onset alopecia areata attributed to ipilimumab

Area of Science:

• Immunology
• Dermatology
• Oncology

Background:

• Ipilimumab is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), used in melanoma treatment.
• Immune-related adverse effects (irAEs) are common toxicities, often affecting the skin.

Observation:

• A patient developed alopecia areata (AA) 1.5 years after ipilimumab therapy.
• Alopecia areata is an autoimmune condition causing hair loss.

Findings:

• This case suggests a potential link between ipilimumab, CTLA-4 dysregulation, and the development of alopecia areata.
• The occurrence of AA as an irAE of ipilimumab is rare but noteworthy.

Implications:

• Increased incidence of alopecia areata may be observed with higher ipilimumab doses for adjuvant melanoma treatment.
• Further research is needed to understand the immunopathogenesis of ipilimumab-induced AA.
• Clinicians should be aware of the potential for delayed irAEs like alopecia areata.